Paul Ranson examines how the UK Biopharma sector must now adapt to a changing landscape following the UK’s vote to leave the EU.
It may come as no surprise that a pre-referendum ‘Brexit’ poll conducted by the UK Pharmaceutical Directors Club of senior management within the UK pharmaceutical industry resulted in a vast majority in favour of ‘Remain’ with local management and head offices concerned about the possibility of the UK exiting the EU and negative implications for their businesses.
This article is an attempt to determine what implementing the referendum result means for the UK and EU pharmaceutical and medical device sectors and to consider practical responses.